Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical StudyMichèle Cavo, Michele Baccarani, Alessandro Gozzetti et al.|Journal of Clinical Oncology|2007Cited by 374
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.Michèle Cavo, Michele Baccarani, Paola Tacchetti et al.|Blood|2009Cited by 48
Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 PatientsElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2010Cited by 7
Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2007Cited by 3
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2009Cited by 1